AKTX Akari Therapeutics Plc

1.94
-0.11  -5%
Previous Close 2.05
Open 2.03
Price To Book 32.33
Market Cap 36,618,132
Shares 18,875,326
Volume 1,093,619
Short Ratio
Av. Daily Volume 900,911

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 staged readouts - no definitive timeline set by company. 2019?
Coversin - CAPSTONE
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 1/2 Part B data due 4Q 2019.
Coversin
Atopic keratoconjunctivitis
Phase 2 further data due 4Q 2019.
Coversin
Bullous Pemphigoid
Pivotal trial to be initiated 4Q 2019.
Coversin
Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA)

Latest News

  1. A Look At Benzinga Pro's Most-Searched Tickers For August 15, 2019
  2. Biopharma News: Why Akari Therapeutics (AKTX) Stock Is Soaring Today
  3. Akari Therapeutics' stock rockets on heavy volume after FDA grants nomacopan 'Fast Track' designation
  4. Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)
  5. Akari Therapeutics announces new data demonstrating synergistic benefits of nomacopan’s bifunctional C5 and LTB4 inhibitory activity in pemphigoid disease
  6. Akari Therapeutics Announces Oral Presentation of Nomacopan Phase II Data in Patients with Bullous Pemphigoid at the 28th European Academy of Dermatology and Venereology (EADV) Congress, October 9-13, 2019
  7. Before You Buy Akari Therapeutics, Plc (NASDAQ:AKTX), Consider Its Volatility
  8. Alexion's Ultomiris Receives EU Approval for PNH in Adults
  9. Akari Therapeutics, Plc Announces $4.5 Million Registered Direct Offering
  10. Alexion Receives FDA Approval for Label Expansion of Soliris
  11. Alexion's sBLA for Ultomiris Gets Priority Review From FDA
  12. Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study
  13. Akari's Lead Candidate Found Safe, Effective In Treating Eye Inflammation
  14. Akari Therapeutics’ Nomacopan Demonstrates Positive Early Safety and Efficacy in Phase I/II Clinical Study in Moderate-to-Severe Atopic Keraconjunctivitis (AKC)
  15. Akari Therapeutics Reports First Quarter 2019 Financial Results And Highlights Recent Clinical Progress
  16. FDA Events Put Healthcare Stocks In The Headlines: Here's One That No One's Talking About Yet
  17. Akari Therapeutics Announces Expanded Ophthalmology Program Based on Positive Emerging Data on LTB4-C5 Dual Action in Surface and Back of the Eye Diseases
  18. The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova
  19. Akari Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights
  20. Positive News in The Biotech, Social Media, Financial & Cannabis Sectors Help the Market Towards New Highs